Human antimicrobial peptides’ antifungal activity against Aspergillus fumigatus
In light of the need for new antifungals, we compared the in vitro antifungal activity of two peptides derived from human lactoferrin (hLF), i.e., hLF(1–11) and hLF(21–31), two analogs of histatin 5, further referred to as dhvar4 and dhvar5, and two ubiquicidin (UBI)-derived peptides, i.e., UBI 18–3...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 2008-11, Vol.27 (11), p.1125-1129 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1129 |
|---|---|
| container_issue | 11 |
| container_start_page | 1125 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 27 |
| creator | Lupetti, A. van Dissel, J. T. Brouwer, C. P. J. M. Nibbering, P. H. |
| description | In light of the need for new antifungals, we compared the in vitro antifungal activity of two peptides derived from human lactoferrin (hLF), i.e., hLF(1–11) and hLF(21–31), two analogs of histatin 5, further referred to as dhvar4 and dhvar5, and two ubiquicidin (UBI)-derived peptides, i.e., UBI 18–35 and UBI 29–41, with that of amphotericin B against
Aspergillus fumigatus
hyphae using the MTT assay. The results revealed a dose-dependent antifungal activity for all peptides, with dhvar5 being the most potent peptide. In addition, hLF(1–11), dhvar5, and UBI 18–35 were effective against
A. fumigatus
conidia. Furthermore, hLF(1–11) did not lyze human erythrocytes, whereas dhvar5 (≥16 μM) and UBI 18–35 (≥20 μM) were hemolytic. Based on these in vitro results and their effectiveness against infections in mice, we concluded that hLF(1–11) and dhvar5 are promising candidates for the development of new agents against
A. fumigatus
infections. |
| doi_str_mv | 10.1007/s10096-008-0553-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_864950544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>864950544</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-6686cedf91d18014198321c46f1d31bde038cc9a085f680d786ecc1b910375183</originalsourceid><addsrcrecordid>eNp1kM9q3DAQh0VpaTZpH6CXYgohJ7cjS5ZHxxDypxAIgfQstLJsFGyvo7ECyamv0dfrk0TpLg0EctGA5vvNDB9jXzh85wDND8qvViUAllDXonx8x1ZcirqUohHv2Qq0kKVuKrHH9oluIWewaT6yPY61Uijlil1fpNFOhZ2WMAYXN-tgh2L28xJaT39___nX6dLU52_rlnAflofC9jZMtBTHNPvYh2FIVHRpDL1dEn1iHzo7kP-8qwfs19npzclFeXl1_vPk-LJ0spFLmfcr59tO85YjcMk1ioo7qTreCr5uPQh0TlvAulMIbYPKO8fXmoNoao7igB1t585xc5c8LWYM5Pww2MlvEhlUUtdQS5nJb6_I202KUz7OVBwVVog6Q3wLZQlE0XdmjmG08cFwMM-2zda2ybbNs23zmDNfd4PTevTtS2KnNwOHO8CSs0MX7eQC_ecqQIGgqsxVW45ya-p9fLnw7e1PSFOYlg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218682889</pqid></control><display><type>article</type><title>Human antimicrobial peptides’ antifungal activity against Aspergillus fumigatus</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Lupetti, A. ; van Dissel, J. T. ; Brouwer, C. P. J. M. ; Nibbering, P. H.</creator><creatorcontrib>Lupetti, A. ; van Dissel, J. T. ; Brouwer, C. P. J. M. ; Nibbering, P. H.</creatorcontrib><description>In light of the need for new antifungals, we compared the in vitro antifungal activity of two peptides derived from human lactoferrin (hLF), i.e., hLF(1–11) and hLF(21–31), two analogs of histatin 5, further referred to as dhvar4 and dhvar5, and two ubiquicidin (UBI)-derived peptides, i.e., UBI 18–35 and UBI 29–41, with that of amphotericin B against
Aspergillus fumigatus
hyphae using the MTT assay. The results revealed a dose-dependent antifungal activity for all peptides, with dhvar5 being the most potent peptide. In addition, hLF(1–11), dhvar5, and UBI 18–35 were effective against
A. fumigatus
conidia. Furthermore, hLF(1–11) did not lyze human erythrocytes, whereas dhvar5 (≥16 μM) and UBI 18–35 (≥20 μM) were hemolytic. Based on these in vitro results and their effectiveness against infections in mice, we concluded that hLF(1–11) and dhvar5 are promising candidates for the development of new agents against
A. fumigatus
infections.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-008-0553-z</identifier><identifier>PMID: 18566844</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Amphotericin B - pharmacology ; Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal agents ; Antifungal Agents - pharmacology ; Antimicrobial Cationic Peptides - pharmacology ; Antimicrobial Cationic Peptides - toxicity ; Aspergillosis - drug therapy ; Aspergillus fumigatus ; Aspergillus fumigatus - drug effects ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Concise Article ; Erythrocytes - drug effects ; Hemolysis ; Humans ; Hyphae - drug effects ; Infectious diseases ; Internal Medicine ; Medical Microbiology ; Medical sciences ; Mice ; Microbial Sensitivity Tests ; Microbial Viability ; Peptides ; Pharmacology. Drug treatments ; Staining and Labeling ; Tetrazolium Salts - metabolism ; Thiazoles - metabolism</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2008-11, Vol.27 (11), p.1125-1129</ispartof><rights>The Author(s) 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer-Verlag 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-6686cedf91d18014198321c46f1d31bde038cc9a085f680d786ecc1b910375183</citedby><cites>FETCH-LOGICAL-c474t-6686cedf91d18014198321c46f1d31bde038cc9a085f680d786ecc1b910375183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10096-008-0553-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10096-008-0553-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20838062$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18566844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lupetti, A.</creatorcontrib><creatorcontrib>van Dissel, J. T.</creatorcontrib><creatorcontrib>Brouwer, C. P. J. M.</creatorcontrib><creatorcontrib>Nibbering, P. H.</creatorcontrib><title>Human antimicrobial peptides’ antifungal activity against Aspergillus fumigatus</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>In light of the need for new antifungals, we compared the in vitro antifungal activity of two peptides derived from human lactoferrin (hLF), i.e., hLF(1–11) and hLF(21–31), two analogs of histatin 5, further referred to as dhvar4 and dhvar5, and two ubiquicidin (UBI)-derived peptides, i.e., UBI 18–35 and UBI 29–41, with that of amphotericin B against
Aspergillus fumigatus
hyphae using the MTT assay. The results revealed a dose-dependent antifungal activity for all peptides, with dhvar5 being the most potent peptide. In addition, hLF(1–11), dhvar5, and UBI 18–35 were effective against
A. fumigatus
conidia. Furthermore, hLF(1–11) did not lyze human erythrocytes, whereas dhvar5 (≥16 μM) and UBI 18–35 (≥20 μM) were hemolytic. Based on these in vitro results and their effectiveness against infections in mice, we concluded that hLF(1–11) and dhvar5 are promising candidates for the development of new agents against
A. fumigatus
infections.</description><subject>Amphotericin B - pharmacology</subject><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal agents</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antimicrobial Cationic Peptides - pharmacology</subject><subject>Antimicrobial Cationic Peptides - toxicity</subject><subject>Aspergillosis - drug therapy</subject><subject>Aspergillus fumigatus</subject><subject>Aspergillus fumigatus - drug effects</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Concise Article</subject><subject>Erythrocytes - drug effects</subject><subject>Hemolysis</subject><subject>Humans</subject><subject>Hyphae - drug effects</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Medical Microbiology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbial Viability</subject><subject>Peptides</subject><subject>Pharmacology. Drug treatments</subject><subject>Staining and Labeling</subject><subject>Tetrazolium Salts - metabolism</subject><subject>Thiazoles - metabolism</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kM9q3DAQh0VpaTZpH6CXYgohJ7cjS5ZHxxDypxAIgfQstLJsFGyvo7ECyamv0dfrk0TpLg0EctGA5vvNDB9jXzh85wDND8qvViUAllDXonx8x1ZcirqUohHv2Qq0kKVuKrHH9oluIWewaT6yPY61Uijlil1fpNFOhZ2WMAYXN-tgh2L28xJaT39___nX6dLU52_rlnAflofC9jZMtBTHNPvYh2FIVHRpDL1dEn1iHzo7kP-8qwfs19npzclFeXl1_vPk-LJ0spFLmfcr59tO85YjcMk1ioo7qTreCr5uPQh0TlvAulMIbYPKO8fXmoNoao7igB1t585xc5c8LWYM5Pww2MlvEhlUUtdQS5nJb6_I202KUz7OVBwVVog6Q3wLZQlE0XdmjmG08cFwMM-2zda2ybbNs23zmDNfd4PTevTtS2KnNwOHO8CSs0MX7eQC_ecqQIGgqsxVW45ya-p9fLnw7e1PSFOYlg</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Lupetti, A.</creator><creator>van Dissel, J. T.</creator><creator>Brouwer, C. P. J. M.</creator><creator>Nibbering, P. H.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7T7</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20081101</creationdate><title>Human antimicrobial peptides’ antifungal activity against Aspergillus fumigatus</title><author>Lupetti, A. ; van Dissel, J. T. ; Brouwer, C. P. J. M. ; Nibbering, P. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-6686cedf91d18014198321c46f1d31bde038cc9a085f680d786ecc1b910375183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Amphotericin B - pharmacology</topic><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal agents</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antimicrobial Cationic Peptides - pharmacology</topic><topic>Antimicrobial Cationic Peptides - toxicity</topic><topic>Aspergillosis - drug therapy</topic><topic>Aspergillus fumigatus</topic><topic>Aspergillus fumigatus - drug effects</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Concise Article</topic><topic>Erythrocytes - drug effects</topic><topic>Hemolysis</topic><topic>Humans</topic><topic>Hyphae - drug effects</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Medical Microbiology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbial Viability</topic><topic>Peptides</topic><topic>Pharmacology. Drug treatments</topic><topic>Staining and Labeling</topic><topic>Tetrazolium Salts - metabolism</topic><topic>Thiazoles - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lupetti, A.</creatorcontrib><creatorcontrib>van Dissel, J. T.</creatorcontrib><creatorcontrib>Brouwer, C. P. J. M.</creatorcontrib><creatorcontrib>Nibbering, P. H.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lupetti, A.</au><au>van Dissel, J. T.</au><au>Brouwer, C. P. J. M.</au><au>Nibbering, P. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human antimicrobial peptides’ antifungal activity against Aspergillus fumigatus</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>27</volume><issue>11</issue><spage>1125</spage><epage>1129</epage><pages>1125-1129</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>In light of the need for new antifungals, we compared the in vitro antifungal activity of two peptides derived from human lactoferrin (hLF), i.e., hLF(1–11) and hLF(21–31), two analogs of histatin 5, further referred to as dhvar4 and dhvar5, and two ubiquicidin (UBI)-derived peptides, i.e., UBI 18–35 and UBI 29–41, with that of amphotericin B against
Aspergillus fumigatus
hyphae using the MTT assay. The results revealed a dose-dependent antifungal activity for all peptides, with dhvar5 being the most potent peptide. In addition, hLF(1–11), dhvar5, and UBI 18–35 were effective against
A. fumigatus
conidia. Furthermore, hLF(1–11) did not lyze human erythrocytes, whereas dhvar5 (≥16 μM) and UBI 18–35 (≥20 μM) were hemolytic. Based on these in vitro results and their effectiveness against infections in mice, we concluded that hLF(1–11) and dhvar5 are promising candidates for the development of new agents against
A. fumigatus
infections.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>18566844</pmid><doi>10.1007/s10096-008-0553-z</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2008-11, Vol.27 (11), p.1125-1129 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_864950544 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Amphotericin B - pharmacology Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents Antifungal Agents - pharmacology Antimicrobial Cationic Peptides - pharmacology Antimicrobial Cationic Peptides - toxicity Aspergillosis - drug therapy Aspergillus fumigatus Aspergillus fumigatus - drug effects Biological and medical sciences Biomedical and Life Sciences Biomedicine Concise Article Erythrocytes - drug effects Hemolysis Humans Hyphae - drug effects Infectious diseases Internal Medicine Medical Microbiology Medical sciences Mice Microbial Sensitivity Tests Microbial Viability Peptides Pharmacology. Drug treatments Staining and Labeling Tetrazolium Salts - metabolism Thiazoles - metabolism |
| title | Human antimicrobial peptides’ antifungal activity against Aspergillus fumigatus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A38%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20antimicrobial%20peptides%E2%80%99%20antifungal%20activity%20against%20Aspergillus%20fumigatus&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Lupetti,%20A.&rft.date=2008-11-01&rft.volume=27&rft.issue=11&rft.spage=1125&rft.epage=1129&rft.pages=1125-1129&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-008-0553-z&rft_dat=%3Cproquest_cross%3E864950544%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218682889&rft_id=info:pmid/18566844&rfr_iscdi=true |